317
Participants
Start Date
January 31, 2020
Primary Completion Date
June 7, 2021
Study Completion Date
June 11, 2021
NYHA assessment
The New York Heart Association (NYHA) functional classification of HF
Serum NT-proBNP concentration
Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
Transthoracic Ecocardiogram
Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
Novartis Investigative Site, San Salvador
Novartis Investigative Site, Santo Domingo
Novartis Investigative Site, Santo Domingo
Novartis Investigative Site, Guatemala City
Novartis Investigative Site, Guatemala City
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY